Cytokinetics (CYTK) Cash & Equivalents (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Cash & Equivalents of $129.8 million for Q1 2026, up 75.33% year-over-year from $74.1 million in Q1 2025, and up 5.98% quarter-over-quarter from $122.5 million in Q4 2025.
Cytokinetics (CYTK) Cash & Equivalents (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Cash & Equivalents for 17 consecutive years, with $129.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 75.33% year-over-year to $129.8 million; the TTM figure through Mar 2026 stood at $129.8 million (up 75.33% YoY), while the FY2025 annual figure was $122.5 million, up 28.65% from the prior year.
- Cash & Equivalents climbed to $129.8 million in Q1 2026 per CYTK's latest filing, from $122.5 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $225.5 million in Q3 2025 and bottomed at $47.3 million in Q3 2024.
- Historically, Cash & Equivalents has averaged $108.7 million across 5 years, with a median of $103.2 million in 2023.
- On a YoY basis, Cash & Equivalents climbed as much as 377.05% in 2025 and fell as far as 60.66% in 2025.
- Cytokinetics' Cash & Equivalents stood at $67.2 million in 2022, then soared by 68.79% to $113.4 million in 2023, then fell by 16.02% to $95.2 million in 2024, then increased by 28.65% to $122.5 million in 2025, then gained by 5.98% to $129.8 million in 2026.
- Business Quant data shows CYTK's Cash & Equivalents at $129.8 million in Q1 2026, $122.5 million in Q4 2025, and $225.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 255.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 255.27 Mn |
| Mar 31, 2026 | 129.84 Mn |
| Dec 31, 2025 | 122.52 Mn |
| Sep 30, 2025 | 225.47 Mn |
| Jun 30, 2025 | 74.94 Mn |
| Mar 31, 2025 | 74.06 Mn |
| Dec 31, 2024 | 95.23 Mn |
| Sep 30, 2024 | 47.26 Mn |
| Jun 30, 2024 | 190.52 Mn |
| Mar 31, 2024 | 120.35 Mn |
| Dec 31, 2023 | 113.40 Mn |
| Sep 30, 2023 | 100.07 Mn |
| Jun 30, 2023 | 69.01 Mn |
| Mar 31, 2023 | 103.22 Mn |
| Dec 31, 2022 | 67.18 Mn |
| Sep 30, 2022 | 106.24 Mn |
| Jun 30, 2022 | 93.63 Mn |
| Mar 31, 2022 | 115.42 Mn |
| Dec 31, 2021 | 112.67 Mn |
| Sep 30, 2021 | 90.56 Mn |